Kenneth Hirsch

Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Management of hepatitis B

A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

Viral RNA Induces Type I Interferon-Dependent Cytokine Release and Cell Death in Mesangial Cells via Melanoma-Differentiation-Associated Gene-5

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

Hepatitis B Virus Infection — Natural History and Clinical Consequences

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

A robust cell culture system supporting the complete life cycle of hepatitis B virus

Management of hepatitis B: 2000—Summary of a workshop

Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*

The Surgical Infection Society Guidelines on Antimicrobial Therapy for Children with Appendicitis

Substituted aryl malonamates as new serine β-lactamase substrates: Structure–activity studies

Viral nephropathy

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

Complementary Role of HCV and HIV in T-Cell Activation and Exhaustion in HIV/HCV Coinfection

Hepatitis B virus infection

Chronic hepatitis B

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

Management of chronic viral hepatitis before and after renal transplantation

Treatment of chronic hepatitis B

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma

Management of Hepatocellular Carcinoma *

Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries

Viral hepatitis B

Novel mechanism of inhibiting β-Lactamases by sulfonylation using β-Sultams

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

Radiation, Inflammation, and Immune Responses in Cancer

Acute appendicitis: modern understanding of pathogenesis, diagnosis, and management

Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B

Caspase Functions in Cell Death and Disease

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

Priming of hepatitis C virus-specific cytotoxic t lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA

An overview on 5α-reductase inhibitors

Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level

Chronic hepatitis B

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

Chronic hepatitis B: Update 2009 #

Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Risk of surgical site infection and efficacy of antibiotic prophylaxis: a cohort study of appendectomy patients in Thailand

Inflammatory caspases are innate immune receptors for intracellular LPS

Antibiotics versus placebo for prevention of postoperative infection after appendicectomy.

Insights into the role of sialylation in cancer progression and metastasis

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer

Genomic Analysis Reveals a Potential Role for Cell Cycle Perturbation in HCV-Mediated Apoptosis of Cultured Hepatocytes

A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA

Hydrolysis of Third-generation Cephalosporins by Class C β-Lactamases

Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens

Hepatocellular carcinoma pathogenesis: from genes to environment

Infection in Solid-Organ Transplant Recipients

Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

Hepatitis B virus induces RNR-R2 expression via DNA damage response activation

The option of HBIG-free prophylaxis against recurrent HBV

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results

Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis

Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B

Appendicitis in children: A ten-year update of therapeutic recommendations

Chronic Hepatitis B: Current Testing Strategies

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Antibiotic Prophylaxis for Appendectomy in Children: Critical Appraisal

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Clinical practice guidelines for antimicrobial prophylaxis in surgery

AmpC β-Lactamases

Aggregation-Induced Emission: Together We Shine, United We Soar!

Bacterial Resistance to β-Lactam Antibiotics:  Compelling Opportunism, Compelling Opportunity

Antibiotics versus placebo for prevention of postoperative infection after appendicectomy.

Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus

Functional evolution of the serine β-lactamase active site

Inhibition of Class A and C β-Lactamases by Diaroyl Phosphates

Advances in the Chemistry of Tetrahydroquinolines

Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease

Neuraminidase inhibitors for preventing and treating influenza in adults and children

Three Decades of β-Lactamase Inhibitors

The Deacylation Mechanism of AmpC β-Lactamase at Ultrahigh Resolution

Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective

Structure-Based Approach for Binding Site Identification on AmpC β-Lactamase

Review of solid-organ transplantation in HIV-infected patients

EASL Recommendations on Treatment of Hepatitis C 2018

Prosthetic Joint Infection

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro

Prevention of Hepatitis B Recurrence after Liver Transplantation

Treatment of Chronic Viral Hepatitis

Tunable protein synthesis by transcript isoforms in human cells

In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil

Prophylactic Antibiotics in Uncomplicated Appendicitis During Childhood - A Prospective Randomised Study

Liver Galβ1,4GlcNAc α2,6-sialyltransferase is down-regulated in human alcoholics: possible cause for the appearance of asialoconjugates

Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS

574 INTERIM 48 WEEK RESULTS OF A RANDOMIZED TRIAL OF EMTRICITABINE/TENOFOVIR DF PLUS/MINUS HBIG WITHDRAWAL IN POST-ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS FOR CHRONIC HEPATITIS B

Kinetics and Mechanism of the Hydrolysis of Depsipeptides Catalyzed by the β-Lactamase of Enterobacter cloacae P99

QSAR study of benzoquinolinones as inhibitors of human type 1 5-α-reductase.

273 SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION